Recent Updates
Recently added Catalysts
KTTA Positive Sentiment Score: 75/100

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Monday, March 24, 2025 2 min read
Key Takeaway: Pasithea Therapeutics Corp. (NASDAQ: KTTA) will present at the 2025 CAGLA NeauxCancer Conference in New Orleans from March 27-29, 2025. The company's Vice President of Business Development, Mathew Lazarus, will discuss the ongoing Phase 1 study results of PAS-004, a macrocyclic MEK inhibitor for neurofibromatosis type 1 and other cancer indications. The conference is a significant global forum in oncology, focusing on groundbreaking advancements in cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pasithea is presenting at a prominent oncology conference.
  • The presentation will showcase promising safety and clinical data for PAS-004.
  • The event gathers leading experts, promoting collaboration in cancer treatment.

Full Press Release Details

-- Conference taking place on March 27-29, 2025 in New Orleans --
-- CAGLA NeauxCancer Conference is a leading global forum in oncology --
MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced its Vice President of Business Development, Mathew Lazarus, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.
Mr. Lazarus’s presentation will provide an overview of Pasithea’s next generation macrocyclic MEK inihibitor, PAS-004, including interim safety, tolerability and pharmacokinetic (PK) data from the Company’s ongoing open-label dose escalation Phase 1 study in advanced cancer patients with MAPK pathway-driven advanced tumors. He will discuss the Company's latest progress in clinical development and how Pasithea is advancing its next-generation molecule to transform cancer and NF1 treatment.
Details of the presentation are as follows:
Event: 2025 CAGLA NeauxCancer Conference
Date: March 28, 2025
Location: The Roosevelt New Orleans
Webcast: CAGLA 2025 Livestreams
The CAGLA NeauxCancer Conference is a premier gathering of leading oncology researchers, industry executives, and medical professionals focused on groundbreaking developments in cancer treatment and care.
For more information about the conference, visit https://cag-la.org/neauxcancer-2025/.
About Pasithea Therapeutics Corp.
Pasithea is a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS). For more information, visit www.pasithea.com.
Pasithea Therapeutics Contact
Corporate Communications
pgaynes@pasithea.com

Tags

CAGLA NeauxCancer Conference
Neurofibromatosis type 1 (NF1)
Clinical development

Frequently Asked Questions

When is the CAGLA NeauxCancer Conference happening?

The conference is scheduled for March 27-29, 2025.

Where will the NeauxCancer Conference take place?

It will be held at The Roosevelt Hotel in New Orleans.

What will Mathew Lazarus present at the conference?

He will present data on Pasithea's PAS-004 and its clinical development.

What is PAS-004 used to treat?

PAS-004 is being developed for neurofibromatosis type 1 and cancer.

How can I get more information about the conference?

Visit the conference website at https://cag-la.org/neauxcancer-2025/.

Tags: KTTA Viatris Investor Conferences Healthcare CAGLA NeauxCancer Conference PAS-004 neurofibromatosis oncology
Last updated: Mar 24, 2025